Servier Acquires Day One for $2.5 Billion, Boosts Rare Cancer Portfolio

Servier finalized its acquisition of Day One Biopharmaceuticals for $2.5 billion, significantly boosting its strategic focus on rare cancer treatments, particularly pediatric low-grade glioma.

The pharmaceutical sector recently saw a major consolidation as Servier, an independent international pharmaceutical group, completed its acquisition of Day One Biopharmaceuticals. This strategic deal expands Servier’s global oncology capabilities, particularly within the challenging rare disease space. Day One specializes in developing and commercializing targeted therapies for life-threatening diseases across all age groups.

Servier offered $21.50 per share for Day One Biopharmaceuticals, valuing the company at approximately $2.5 billion in total equity. This transaction represents a direct step towards Servier’s 2030 ambition to fortify its rare cancer footprint and strengthen its leadership in specific oncology areas.

Olivier Laureau, President of Servier, stated the acquisition specifically targets pediatric low-grade glioma, a common childhood brain tumor. He emphasized the move will enhance innovation and deliver meaningful medicines to affected children and families. Day One’s portfolio includes OJEMDA (tovorafenib), an FDA-approved medicine for pediatric low-grade glioma, already marketed in the United States. This addition provides Servier with an immediate revenue-generating product and established market presence.

Beyond OJEMDA, the acquisition also strengthens Servier's oncology pipeline from early clinical to Phase 3 development. These assets include Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC), and DAY301, a targeted therapy in rare cancers. Day One shares ceased trading on Nasdaq following the tender offer's completion, and Servier intends to delist them.

This move establishes Servier as a stronger force in both pediatric low-grade glioma treatment and the broader rare oncology market. The integration of Day One's scientific and clinical capabilities allows Servier to accelerate the development and delivery of specialized, targeted therapies for patients with significant unmet medical needs, particularly within the United States.

The industry will now closely monitor Servier's execution of this integration, observing its subsequent impact on rare cancer patient outcomes and the evolving competitive landscape for specialized oncology treatments.